Guselkumab Injection Market Growth, Forecast & Key Players

Published: 2026-05-18
Views: 1
Author: Shivani
Published in: Business

According to a newly published market research report by 24LifeSciences, global Guselkumab Injection market was valued at USD 1.8 billion in 2025 and is projected to reach USD 3.2 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.1% during the forecast period 20262034.

Guselkumab, marketed under the brand name Tremfya, is a human monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23). It is primarily used for the treatment of moderate-to-severe plaque psoriasis and psoriatic arthritis. By inhibiting IL-23 mediated signaling, the drug demonstrates superior efficacy in managing these chronic autoimmune conditions compared to traditional therapies.

Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/15156/guselkumab-injection-market

Rising Prevalence of Autoimmune Disorders Fuels Market Expansion

The increasing global burden of psoriasis and psoriatic arthritis, affecting approximately 125 million people worldwide, remains the primary growth driver for Guselkumab adoption. The expanding understanding of IL-23's role in inflammatory pathways has positioned Guselkumab as a first-line biologic therapy, particularly for patients who fail conventional treatments.

Furthermore, the product's favorable safety profile and demonstrated long-term efficacy in clinical trials have accelerated its incorporation into treatment guidelines across major markets. Physicians increasingly prefer this targeted biologic approach due to its durable response rates and convenient dosing schedule.

Biologic Treatment Paradigm Shift Enhances Market Prospects

The pharmaceutical industry's transition toward precision biologic therapies has significantly benefited Guselkumab's market position. Recent advancements in biotechnology manufacturing have improved production scalability while maintaining stringent quality standards for monoclonal antibodies.

Ongoing clinical research exploring expanded indications, including potential applications in other IL-23 mediated diseases, promises to create additional growth avenues. Moreover, healthcare systems worldwide are gradually improving reimbursement policies for advanced biologic treatments, enhancing patient access.

Market Challenges: High Costs and Intense Competition

The Guselkumab market faces notable challenges that could impact growth trajectories:

• Significant treatment costs exceeding $50,000 annually in some regions

• Complex regulatory pathways for biologic drugs across different jurisdictions

• Competition from alternative biologics including IL-17 and TNF-alpha inhibitors

• Emerging biosimilar threats as key patents approach expiration

These factors create accessibility barriers in cost-sensitive markets and require manufacturers to implement strategic pricing and market access approaches.

Get the Complete Report & Table of Contents: https://www.24lifesciences.com/guselkumab-injection-market-15156

North America Dominates the Global Guselkumab Landscape

The North American region, led by the U.S., commands the largest share of global Guselkumab revenues, accounting for approximately 42% of the market. This leadership position stems from several key factors:

• High disease prevalence and early diagnosis rates

• Advanced healthcare infrastructure favoring biologic adoption

• Comprehensive insurance coverage for innovative therapies

• Strong physician familiarity with IL-23 inhibitors

Meanwhile, the Asia-Pacific region, particularly China, is projected to exhibit the fastest growth through 2034, driven by expanding healthcare access and increasing awareness of advanced treatment options.

Specialty Clinics Emerge as Primary Treatment Centers

By end-user, specialty clinics (particularly dermatology and rheumatology practices) have become the dominant channel for Guselkumab administration. These settings combine specialized expertise with the infrastructure needed for proper biologic storage and administration, creating an ideal environment for patient care.

In terms of dosage forms, the 100mg injection maintains market leadership due to its established efficacy profile and alignment with standard treatment protocols. This concentration has demonstrated optimal therapeutic outcomes across multiple clinical studies.

Competitive Landscape: Janssen Maintains Stronghold

The global Guselkumab market demonstrates high consolidation, with Janssen Biotech (Johnson & Johnson) controlling approximately 70% of market share through its Tremfya brand. The competitive environment emphasizes:

• Product efficacy and safety differentiation

• Patent protection strategies

• Clinical evidence generation

• Specialty distribution networks

Key companies profiled in the report include:

• Janssen Biotech (Johnson & Johnson)

• Viatris (Mylan)

• Biocon

• Amgen

• Novartis (Sandoz)

• Pfizer

• Jiangsu Hengrui Medicine

• and More

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/guselkumab-injection-market-15156

Emerging Markets and Innovation Present Growth Opportunities

Significant untapped potential exists in developing economies across Asia-Pacific and Latin America, where improving healthcare infrastructure and rising disposable incomes are expanding access to biologic therapies. Additionally, the development of novel formulations and combination treatment approaches could further enhance Guselkumab's clinical utility and market penetration.

Access the Full Report

Download a Free Sample Report (PDF):
https://www.24lifesciences.com/download-sample/15156/guselkumab-injection-market

Get the Complete Report & Table of Contents:
https://www.24lifesciences.com/guselkumab-injection-market-15156

About 24LifeSciences

24LifeSciencesis a leading provider of market intelligence and strategic research reports across pharmaceuticals, biotechnology, medical devices, and healthcare technologies. Our reports are designed to support data-driven decision-making for manufacturers, healthcare providers, investors, consultants, and policy makers worldwide.

Follow us on LinkedIn:
https://www.linkedin.com/company/lifesciences24/